medigraphic.com
Órgano Oficial de la Asociación Mexicana de Hepatología

2018, Número 4

<< Anterior Siguiente >>

Ann Hepatol 2018; 17 (4)


Frequency and Characteristics of Occult Hepatitis B Infection Among Hepatocellular Carcinoma Patients in Japan

Muto J, Sugiyama M, Shirabe K, Mukaide M, Kirikae-Muto I, Ikegami T, Yoshizumi T, Yamashita Yo-ichi, Maehara Y, Mizokami M

Idioma: Ingles.
Referencias bibliográficas: 15
Paginas: 596-603
Archivo PDF: 196.55 Kb.


RESUMEN

Sin resumen.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA: a cancer journal for clinicians 2005; 55: 74- 108.

  2. Lai CL, Ratziu V, Yuen MF, Poynard T. Viral hepatitis B. Lancet 2003; 362: 2089-94.

  3. Ikeda K, Marusawa H, Osaki Y, Nakamura T, Kitajima N, Yamashita Y, Kudo M, et al. Antibody to hepatitis B core antigen and risk for hepatitis C-related hepatocellular carcinoma: a prospective study. Annals of internal medicine 2007; 146: 649-56.

  4. Ohki T, Tateishi R, Goto E, Sato T, Masuzaki R, Imamura J, Goto T, et al. Influence of anti-HBc seropositivity on the risk of hepatocellular carcinoma in HCV-infected patients after adjusting for confounding factors. Journal of viral hepatitis 2010; 17: 91-7.

  5. Torbenson M, Thomas DL. Occult hepatitis B. The Lancet infectious diseases 2002; 2: 479-86.

  6. Raimondo G, Pollicino T, Cacciola I, Squadrito G. Occult hepatitis B virus infection. Journal of hepatology 2007; 46: 160-70.

  7. Chang ML, Lin YJ, Chang CJ, Yeh C, Chen TC, Yeh TS, Lee WC, et al. Occult and Overt HBV Co-Infections Independently Predict Postoperative Prognosis in HCV-Associated Hepatocellular Carcinoma. PloS one 2013; 8: e64891.

  8. Wong DK, Huang FY, Lai CL, Poon RT, Seto WK, Fung J, Hung IF. Occult hepatitis B infection and HBV replicative activity in patients with cryptogenic cause of hepatocellular carcinoma. Hepatology 2011; 54: 829-36.

  9. Pollicino T, Squadrito G, Cerenzia G, Cacciola I, Raffa G, Craxi A, Farinati F. Hepatitis B virus maintains its pro-oncogenic properties in the case of occult HBV infection. Gastroenterology 2004; 126: 102-10.

  10. Squadrito G, Cacciola I, Alibrandi A, Pollicino T, Raimondo G. Impact of occult hepatitis B virus infection on the outcome of chronic hepatitis C. Journal of hepatology 2013; 59: 696-700.

  11. Lok AS, Everhart JE, Di Bisceglie AM, Kim HY, Hussain M, Morgan TR. Occult and previous hepatitis B virus infection are not associated with hepatocellular carcinoma in United States patients with chronic hepatitis C. Hepatology 2011; 54: 434-42.

  12. Kitab B, Ezzikouri S, Alaoui R, Nadir S, Badre W, Trepo C, Chemin I. Occult HBV infection in Morocco: from chronic hepatitis to hepatocellular carcinoma. Liver international: official journal of the International Association for the Study of the Liver 2014.

  13. Fujimoto A, Totoki Y, Abe T, Boroevich KA, Hosoda F, Nguyen HH, Aoki M, Hosono N. Whole-genome sequencing of liver cancers identifies etiological influences on mutation patterns and recurrent mutations in chromatin regulators. Nature genetics 2012; 44: 760-4.

  14. Sung WK, Zheng H, Li S, Chen R, Liu X, Li Y, Lee NP. Genome- wide survey of recurrent HBV integration in hepatocellular carcinoma. Nature genetics 2012; 44: 765-9.

  15. Kim HE, Kim DG, Lee KJ, Son JG, Song MY, Park YM, Kim JJ. Frequent amplification of CENPF, GMNN and CDK13 genes in hepatocellular carcinomas. PloS ONE 2012; 7: e43223.




2020     |     www.medigraphic.com